Cocrystal Pharma - COCP Company Value to Revenue

Cocrystal Pharma Inc (COCP) - corporate logo

Cocrystal Pharma, Inc. (COCP) utilizes a CDMO network for drug production, and its financial stability depends on external funding due to a lack of profitable products. The current price-to-sales valuation reflects the fundamental value trend, where 34883.72 is the current level of the metric. Meanwhile, robotic synthesis and computer modeling accelerate the search for active molecules without increasing headcount.

Cocrystal Pharma - COCP Company Value to Revenue (period 11/23/2025 - 11/20/2026)

Financial and market metric breakdowns for Cocrystal Pharma (COCP)

Fundamental company valuation:COCP - cocrystalpharma.com
Original product of cocrystalpharma.com

Cocrystal Pharma, Inc. (COCP) focus on developing antiviral small molecules within clinical trials makes revenue an unstable factor, necessitating a business valuation based on enterprise value minus net debt. This metric determines the real price of the asset relative to sales volume; therefore, the current enterprise value-to-revenue ratio allows for the identification of either a risk of overpayment or an undervaluation of capital.